Back to top
more

Tempus AI, Inc. (TEM)

(Delayed Data from NSDQ)

$66.17 USD

66.17
11,900,400

-6.52 (-8.97%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $65.69 -0.48 (-0.73%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 247)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Tracey Ryniec headshot

Cathie Wood's ARKK ETF is Back: Buy It or Not?

by Tracey Ryniec

Tracey Ryniec, Zacks Senior Stock Strategist, checks in on ARK Invest's flagship ETF which is seeing big cash inflows again in 2025.

Sridatri Sarkar headshot

Strategic Partnerships Power Tempus AI's Healthcare Expansion

by Sridatri Sarkar

TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.

Urmimala Biswas headshot

Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?

by Urmimala Biswas

Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.

Sridatri Sarkar headshot

TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?

by Sridatri Sarkar

Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.

Zacks Equity Research

Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market

by Zacks Equity Research

Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.

Zacks Equity Research

Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Tempus (TEM) delivered earnings and revenue surprises of +4.35% and +5.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of +180.00% and +24.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Hims & Hers Redefines Virtual Care With Integrated Tech Platforms

by Debanjana Dey

HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.

Sridatri Sarkar headshot

Tempus AI Targets Breast Cancer With Expanded Next - AI Platform

by Sridatri Sarkar

TEM expands its AI-driven Tempus Next platform into breast cancer, targeting key testing gaps to improve care delivery.